These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24028818)

  • 1. Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents.
    Georgakopoulou EA; Scully C
    Oral Dis; 2015 Apr; 21(3):273-82. PubMed ID: 24028818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic use of non-biologic corticosteroids in orofacial diseases.
    Georgakopoulou EA; Scully C
    Oral Dis; 2014 Mar; 20(2):127-35. PubMed ID: 23746234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic use of non-biologics in orofacial diseases: 2. Purine synthesis inhibitors.
    Georgakopoulou EA; Scully C
    Oral Dis; 2014 Nov; 20(8):732-9. PubMed ID: 23837909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology and Therapeutics of Corticosteroids Sparing Maintenance Immunosuppressive/Adjunct Therapy Drugs.
    Sehgal VN; Malhotra R
    Skinmed; 2019; 17(3):172-179. PubMed ID: 31496471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgA pemphigus: case series with emphasis on therapeutic response.
    Moreno AC; Santi CG; Gabbi TV; Aoki V; Hashimoto T; Maruta CW
    J Am Acad Dermatol; 2014 Jan; 70(1):200-1. PubMed ID: 24355273
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of erosive pustular dermatosis: a systematic review of the literature.
    Lee KH; Carley SK; Kraus CN; Mesinkovska NA
    Int J Dermatol; 2020 Jul; 59(7):770-786. PubMed ID: 31904115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical immunomodulators for management of oral mucosal conditions, a systematic review; part I: calcineurin inhibitors.
    Elad S; Epstein JB; Yarom N; Drucker S; Tzach R; von Bültzingslöwen I
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):713-26. PubMed ID: 21091397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.
    Kurita T; Yasuda S; Amengual O; Atsumi T
    Lupus; 2015 Jan; 24(1):3-9. PubMed ID: 25297551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
    Kuhn A; Aberer E; Bata-Csörgő Z; Caproni M; Dreher A; Frances C; Gläser R; Klötgen HW; Landmann A; Marinovic B; Nyberg F; Olteanu R; Ranki A; Szepietowski JC; Volc-Platzer B
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):389-404. PubMed ID: 27859683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Behçet's disease--an update.
    Kaklamani VG; Kaklamanis PG
    Semin Arthritis Rheum; 2001 Apr; 30(5):299-312. PubMed ID: 11303303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with severe oral mucosal disease.
    Kim Y; Greenberg MS
    Alpha Omegan; 2001; 94(2):18-23. PubMed ID: 11480183
    [No Abstract]   [Full Text] [Related]  

  • 12. [Behcet's disease therapy review].
    Vidaller Palacín A; Robert Olalla J; Sanuy Jiménez B; Rufi Rigau G; Folch Civit J; Charte González A
    An Med Interna; 2002 Nov; 19(11):594-8. PubMed ID: 12522899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens.
    Fiorucci E; Lucantoni G; Paone G; Zotti M; Li BE; Serpilli M; Regimenti P; Cammarella I; Puglisi G; Schmid G
    Eur Rev Med Pharmacol Sci; 2008; 12(2):105-11. PubMed ID: 18575160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory mucous membrane pemphigoid which developed after allogeneic stem cell transplantation and was successfully treated with rituximab.
    Nishimura R; Fujimoto N; Kito K; Uchiyama K; Koga H; Hodohara K; Hashimoto T; Fujiyama Y; Tanaka T
    Eur J Dermatol; 2013; 23(4):562-4. PubMed ID: 24001878
    [No Abstract]   [Full Text] [Related]  

  • 15. [Auto-immune hepatitis: therapeutic management].
    Pariente A
    Gastroenterol Clin Biol; 2003 May; 27(5 Suppl):B13-9. PubMed ID: 12843932
    [No Abstract]   [Full Text] [Related]  

  • 16. Recalcitrant pemphigus vulgaris responding to systemic tacrolimus.
    Büsing V; Kern JS; Bruckner-Tuderman L; Hofmann SC
    Dermatology; 2010; 221(2):122-6. PubMed ID: 20587990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
    Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
    Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous lupus erythematosus: update of therapeutic options part II.
    Kuhn A; Ruland V; Bonsmann G
    J Am Acad Dermatol; 2011 Dec; 65(6):e195-213. PubMed ID: 20800319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
    Schiff J; Cole E; Cantarovich M
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):374-84. PubMed ID: 17699437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
    Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
    Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.